Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI - Takeaways - MDSpire

Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI

  • By

  • Ran Yan

  • Wakana Murakami

  • Shabnam Mortazavi

  • Tiffany Yu

  • Fang-I. Chu

  • Stephanie Lee-Felker

  • Kyunghyun Sung

  • April 29, 2024

  • 0 min

Share

  • 1

    Breast cancer is the most common noncutaneous malignancy in women and the second leading cause of cancer-related deaths.

  • 2

    MRI screening is recommended for women with a lifetime breast cancer risk exceeding 20% to improve detection and survival.

  • 3

    Background parenchymal enhancement (BPE) may correlate with breast cancer risk, but its predictive value remains controversial.

  • 4

    The study aimed to quantitatively assess BPE in women with varying lifetime risks and BRCA mutation statuses.

  • 5

    Quantitative BPE measurements could enhance breast cancer risk stratification and improve MRI diagnostic accuracy.

Original Source(s)

Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI

  • by Ran Yan, Wakana Murakami, Shabnam Mortazavi, Tiffany Yu, Fang-I. Chu, Stephanie Lee-Felker, Kyunghyun Sung

  • April 29, 2024

Related Content

Transforming Imaging Data into Pathological Insights: The Role of AI in Mammographic Risk Assessment and Tumor Biology Understanding

Innovations Shaping Women’s Cancer Care in 2026

As we move through 2026, new technologies and refined surgical techniques are transforming outcomes for women facing cancer diagnoses.

  • by

  • March 4, 2026

  • 6 min
Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy